Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.

Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.
四川科倫博泰生物醫藥股份有限公司
(A joint stock company incorporated in the People's Republic of China with limited liability)
(Stock Code: 6990)

SUPPLEMENTARY ANNOUNCEMENT
CONTINUING CONNECTED TRANSACTION
2026 R&D-RELATED GOODS FRAMEWORK AGREEMENT

Reference is made to the announcement of the Company dated January 16, 2026 in relation to the continuing connected transaction of the 2026 R&D-related Goods Framework Agreement (the "**Announcement**"). Unless otherwise defined, capitalized terms used herein shall have the same meanings as those defined in the Announcement. The Board wishes to advise that no transaction under the 2026 R&D-related Goods Framework Agreement was conducted between January 1 and 16, 2026 (both days inclusive) and provide supplemental information in relation to pricing policy of the procurement of R&D-related Goods from China Resources Kelun and/or its subsidiaries as contemplated under the 2026 R&D-related Goods Framework Agreement.

Pricing Policy

As disclosed in the Announcement, the price payable by the Company for procuring the R&D related Goods will be determined through arm's length negotiation primarily based on the production cost of the R&D-related Goods, the sales price to external third parties and our procurement volume, with reference to a number of factors applicable to all suppliers, including but not limited to the prevailing market price of the relevant goods of same quality, specifications of the products, delivery capability, response time and the fees charged for historical transactions of similar nature.

To ensure that the transactions are conducted on normal commercial terms or better than terms available from independent third parties, the management of the Company will also determine the prices and terms of the procurement of R&D-related Goods by the Group from China Resources Kelun and/or its subsidiaries with reference to:

(1) the prices of similar R&D-related goods in comparable transactions conducted by the Group with independent third parties during the same period (if any), to ensure that the price to be paid by the Company for the R&D-related Goods to China Resources Kelun will not be higher than the price paid by the Company in comparable transactions; and

(2) the recent market prices of comparable transactions, by making enquiries on market prices and the production cost (if available) of similar R&D-related goods with industry players and conducting researches on industry websites, and then compare the references with the prices quoted by China Resources Kelun to ensure that the price to be paid by the Company for the R&D-related Goods to China Resources Kelun will not be higher than the price offered by independent suppliers to the Company. To implement this policy, the management of the Company would solicit at least two other contemporaneous transactions with independent third parties for the R&D-related goods in similar quantities and the same quality for comparison.

In implementing the above pricing policies and principles, the internal audit department of the Company and the departments responsible for the connected transactions of the Company will assess the terms of proposed connected transactions, in particular the pricing, with reference to the above pricing policies and principles. Such internal audit department will be monitored by the audit committee of the Company. The final price will be determined after confirmation of the departments responsible for the connected transactions of the Company with reference to the above pricing policies and principles and after the approval of the general manager or the deputy general manager or other authorized management personnel of the Company or the relevant subsidiaries.

By order of the Board
Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.
LIU Gexin
Chairman of the Board and Non-executive Director

Hong Kong, January 23, 2026

As at the date of this announcement, the Board comprises Mr. LIU Gexin as the chairman of the Board and non-executive Director, Dr. GE Junyou as executive Director, Mr. LIU Sichuan, Mr. LAI Degui, Mr. FENG Hao, Ms. LIAO Yihong and Mr. ZENG Xuebo as non-executive Directors, and Dr. ZHENG Qiang, Dr. TU Wenwei, Dr. JIN Jinping and Dr. LI Yuedong as independent non-executive Directors.